

The Manager
Companies Announcement Platform
SIM Venture Securities Exchange

17 December 2012

***SoloFlow*[®] Successfully Completes the CE Mark Conformity Process**

HIGHLIGHTS:

- **CE Mark (for product sale & supply in Europe) conformity process for the *SoloFlow*[®] Non Injection Needle successfully completed.**
 - ***SoloFlow*[®] can now be sold commercially throughout the European Union (EU).**
-

The Board of Telezon[®] Limited ("the Company") is pleased to advise the market that the Company's flagship *SoloFlow*[®] Non Injection Needle has successfully completed all mandatory testing and validation for the CE Mark.

This is a significant commercial milestone for Telezon, as *SoloFlow*[®], a 'Class 1 Sterile Device', will now be affixed with the CE Mark in accordance with directive 93/42/EEC and can be sold throughout the European Union.

CE Marking on a product is a manufacturer's declaration that the product has been **assessed before being placed on the market** and meets EU safety, health and environmental protection requirements¹.

The Company's *SoloFlow*[®] needle has already achieved FDA registration (US Food and Drug Administration) allowing commercial distribution of this product in the US Market. After working industriously with a CE Mark-approved commercial partner since August (to ensure compliance with mandatory standards), Telezon can now add the CE Mark to their noteworthy achievements for the *SoloFlow*[®] needle.

¹ European Commission: Enterprise & Industry. 2012. European Commission Enterprise and Industry DG, B - 1049 Brussels (Belgium). Viewed 12 Dec 2012. <<http://ec.europa.eu/enterprise/policies/single-market-goods/cemarking/>>



1 Dalmore Drive, Caribbean Business Park, Scoresby VIC 3179
PO Box 485, South Melbourne VIC 3205
Tel: 61 03 9763 8605 Fax: 61 03 9763 2714
www.telezon.com

The Company is currently pursuing capital investment to accelerate commercialisation of its other world-patented products and technologies – including *CoreIT® Advanced Moulding Technology*; *Blunt SoloFlow®*; *DuoDraw®*; and *PolyDermic®* – and to achieve even greater global reach. The Company's solid record of accomplishments and the expanding markets available to the *SoloFlow®* Non Injection Needle further demonstrates the global importance of our products and supports this pursuit of investment.

To receive updates of the Company's achievements and activities, please register your details at:

<http://www.telezon.com/contact-us/register-updates>

For and on behalf of Telezon Limited,

Dr Michelle Carr
Director & Co. Secretary
T: 61 03 9763 8605 F: 61 03 9763 2714